NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
…, DL Bushnell, WW De Herder, SJ Goldsmith… - Pancreas, 2010 - journals.lww.com
Well-differentiated neuroendocrine tumors (NETs) of the stomach and pancreas represent 2
major subtypes of gastrointestinal NETs. Historically, there has been little consensus on the …
major subtypes of gastrointestinal NETs. Historically, there has been little consensus on the …
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum …
…, MM Hassan, EA Woltering, RT Jensen, SJ Goldsmith… - Pancreas, 2010 - journals.lww.com
Well-differentiated neuroendocrine tumors (NETs) of the jejunum, ileum, and appendix are
also collectively known as midgut carcinoids. Similar to NETs in general, the diagnosed …
also collectively known as midgut carcinoids. Similar to NETs in general, the diagnosed …
[PDF][PDF] Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate …
…, S Vallabhajosula, SJ Goldsmith - Journal of Clinical …, 2005 - hilapharma.com
Purpose To determine the maximum tolerated dose (MTD), toxicity, human anti-J591 response,
pharmacokinetics (PK), organ dosimetry, targeting, and biologic activity of 177Lutetium-…
pharmacokinetics (PK), organ dosimetry, targeting, and biologic activity of 177Lutetium-…
Clinical role of FDG PET in evaluation of cancer patients
L Kostakoglu, H Agress Jr, SJ Goldsmith - Radiographics, 2003 - pubs.rsna.org
Positron emission tomography (PET) is a diagnostic imaging technique that allows identification
of biochemical and physiologic alterations in tumors. Use of PET performed with 2-[…
of biochemical and physiologic alterations in tumors. Use of PET performed with 2-[…
Phase II study of lutetium-177–labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer
Purpose: To assess the efficacy of a single infusion of radiolabeled anti-prostate-specific
membrane antigen (PSMA) monoclonal antibody J591 (lutetium-177; 177 Lu) by prostate-…
membrane antigen (PSMA) monoclonal antibody J591 (lutetium-177; 177 Lu) by prostate-…
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease
…, JP Leonard, I Kuji, H Zoe, SJ Goldsmith - Journal of Nuclear …, 2002 - Soc Nuclear Med
Early identification of chemotherapy-refractory lymphoma patients provides a basis for
alternative treatment strategies. Metabolic imaging with 18 F-FDG PET offers functional tissue …
alternative treatment strategies. Metabolic imaging with 18 F-FDG PET offers functional tissue …
[HTML][HTML] Possible axonal regrowth in late recovery from the minimally conscious state
…, S Vallabhajosula, SJ Goldsmith… - The Journal of …, 2006 - Am Soc Clin Investig
We used diffusion tensor imaging (DTI) to study 2 patients with traumatic brain injury. The
first patient recovered reliable expressive language after 19 years in a minimally conscious …
first patient recovered reliable expressive language after 19 years in a minimally conscious …
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0
…, C Divgi, MJ Gelfand, SJ Goldsmith… - Journal of Nuclear …, 2012 - Soc Nuclear Med
THERAPY OF THYROID DISEASE WITH 131I• Silberstein et al. 1633 patients throughout
the United States. Existing practice guidelines will be reviewed for revision or renewal, as …
the United States. Existing practice guidelines will be reviewed for revision or renewal, as …
[PDF][PDF] Phase I trial of yttrium-90—labeled anti—prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
…, L Kostakoglu, S Vallabhajosula, SJ Goldsmith… - Journal of clinical …, 2004 - Citeseer
Purpose To determine the maximum-tolerated dose (MTD), toxicity, human antihuman
antibody (HAHA) response, pharmacokinetics, organ dosimetry, targeting, and preliminary …
antibody (HAHA) response, pharmacokinetics, organ dosimetry, targeting, and preliminary …
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen
…, MA Joyce, M Milowsky, DM Nanus, SJ Goldsmith - The Journal of …, 2003 - Elsevier
PURPOSE: We performed an interim analysis of imaging data collected in 2 phase I
radioimmunotherapy trials to determine the ability of monoclonal antibody (mAb) J591 directed to …
radioimmunotherapy trials to determine the ability of monoclonal antibody (mAb) J591 directed to …